Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: sarembock ij. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ; REPLACE-1 Investigators. Lincoff AM, et al. Among authors: sarembock ij. Am J Cardiol. 2004 May 1;93(9):1092-6. doi: 10.1016/j.amjcard.2004.01.033. Am J Cardiol. 2004. PMID: 15110198 Clinical Trial.
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: sarembock ij. JAMA. 2004 Aug 11;292(6):696-703. doi: 10.1001/jama.292.6.696. JAMA. 2004. PMID: 15304466 Clinical Trial.
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ. Cohen DJ, et al. Among authors: sarembock ij. J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800. doi: 10.1016/j.jacc.2004.05.085. J Am Coll Cardiol. 2004. PMID: 15519009 Free article. Clinical Trial.
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM. Gurm HS, et al. Among authors: sarembock ij. J Am Coll Cardiol. 2005 Jun 21;45(12):1932-8. doi: 10.1016/j.jacc.2005.02.074. J Am Coll Cardiol. 2005. PMID: 15963389 Free article. Clinical Trial.
The truth and consequences of the COURAGE trial.
Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, Stone GW. Kereiakes DJ, et al. Among authors: sarembock ij. J Am Coll Cardiol. 2007 Oct 16;50(16):1598-603. doi: 10.1016/j.jacc.2007.07.063. Epub 2007 Sep 17. J Am Coll Cardiol. 2007. PMID: 17936161 Free article.
Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD. Kereiakes DJ, et al. Among authors: sarembock ij. Circ Cardiovasc Interv. 2015 Apr;8(4):e002372. doi: 10.1161/CIRCINTERVENTIONS.114.002372. Circ Cardiovasc Interv. 2015. PMID: 25855680 Free article. Clinical Trial.
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
BARI 2D Study Group; Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. BARI 2D Study Group, et al. N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7. N Engl J Med. 2009. PMID: 19502645 Free PMC article. Clinical Trial.
116 results